Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Nick Maisey"'
Autor:
Nick Maisey
Publikováno v:
Cancer Investigation. 25:589-593
The kinase inhibitors sorafinib and sunitinib have demonstrated significant activity in renal cell carcinoma (RCC), and are now approved by the FDA for use in advanced disease. There still remains a need for novel therapies. Our group were the first
Autor:
Ian Chau, Stephen J. Gwyther, Helen Marshall, Tim Maughan, John Wagstaff, Mark A. Hill, Jonathan Wadsley, Alfred Oliver, Catherine Lowe, Gary Middleton, S. Myint, Vicky Napp, Sarah Brown, Denise Blake, Simon Gollins, Sarah Slater, Matthew T. Seymour, Susan D. Richman, John Bridgewater, Nick Maisey
Publikováno v:
European Journal of Cancer. 49(16)
Background: The main toxicity of irinotecan in advanced colorectal cancer (CRC) is delayed diarrhoea. Intestinal SN-38, released by deconjugation of the parent glucuronide excreted into the bile or produced in situ by intestinal carboxylesterase, is
Autor:
Kim Benstead, Stephen Falk, Nick Maisey, Ian Chau, Ann O'Callaghan, Tim Maughan, Helen Marshall, Gary Middleton, Mark A. Hill, Susan D. Richman, Sarah Brown, Jennifer F Seligmann, Phil Quirke, Philip A. Chambers, Jonathan Wadsley, Vicky Napp, Matthew T. Seymour, Lesley Dawson, Catherine Lowe, Stephen J. Gwyther, Alfred Oliver
Publikováno v:
The Lancet Oncology. 14(8)
Background: Therapeutic antibodies targeting EGFR have activity in advanced colorectal cancer, but results from clinical trials are inconsistent and the population in which most benefit is derived is uncertain. Our aim was to assess the addition of p
Publikováno v:
Recent patents on anti-cancer drug discovery. 5(2)
Targeting the epidermal growth factor receptor (EGFR), an important component in carcinogenesis, is an attractive therapeutic option for selective anticancer therapy. Several EGFR inhibitors, mostly monoclonal antibodies and tyrosine kinase inhibitor
Autor:
Eleni Timotheadou, Susan Hoare, Frances R. Balkwill, NF Li, C. Lee, Robert Corringham, Michelle Harrison, Eva Obermueller, Martin Gore, Tim Eisen, D. Mike King, Kellie A. Charles, Kim Edmonds, Nick Maisey, Roger A'Hern, Mark DeWitte, Kate Hall, David Chao
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 25(29)
PurposeTumor necrosis factor α (TNF-α) may play a role in renal cell carcinoma (RCC). We performed two sequential phase II studies of infliximab, an anti–TNF-α monoclonal antibody, in patients with immunotherapy-resistant or refractory RCC.Patie